Diligent Pharma Named to the Inc. 5000 List for the Second Consecutive Year

August 11, 2026 — We are proud to share that for the second consecutive year, Diligent Pharma has been named to the Inc. 5000 list of the fastest growing privately held companies in America. 

Published each year by Inc. magazine, the list honors private companies that have demonstrated exceptional revenue growth over a three-year period. Among this year's honorees, Diligent ranked No. 1,523 overall and No. 6 in the Pharmaceutical and Biotech sector. 

The Inc. 5000 provides a data-driven snapshot of the most successful companies within the economy's most dynamic segment—its independent, entrepreneurial businesses. Companies on the 2026 list are ranked according to percentage revenue growth from 2022 to 2025. Past honorees include Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, and Patagonia. 

Diligent Pharma's back-to-back recognition reflects a broader shift underway in clinical research: mounting pressure to accelerate trials without compromising quality. Every delay in a clinical trial carries a cost—not only for Sponsors launching trials but also for patients waiting for new medicines. Yet the industry's standard approach to qualifying Vendors remains a major source of delayed trial startup: a redundant, largely manual process in which the same Vendor is qualified repeatedly, once for every new Sponsor relationship. The burden is particularly acute for the industry's newest entrants—biotechs and emerging Vendors with lean teams—for whom spending scarce subject matter expertise on repetitive qualification work is not only inefficient but a trade-off against managing higher stakes activities that determine trial success. 

Diligent is changing that equation with a shared qualification ecosystem. Our centralized platform and rigorous qualification approach—designed to meet the risk-based standards regulators now expect—raise the bar for quality and compliance while reducing timelines and costs for Sponsors and Vendors alike. The growth recognized in this year’s award is a testament to our clients’ commitment and partnership in advancing this model alongside us. Every new partner strengthens our mission to bring medicines to patients faster.  

"Every company on the Inc. 5000 has a story of perseverance, smart decision making, and a refusal to sit still," says Mike Hofman, editor-in-chief of Inc. "Their growth reflects more than strong financial performance—it reflects creativity, resilience, and the customer focus required to build companies that make a lasting impact. We congratulate all honorees on this significant achievement." 

About Diligent Pharma 

Diligent Pharma is a Quality and Compliance organization serving the Life Sciences. We connect Sponsors and Vendors on a secure platform that streamlines Vendor discovery, qualification, and management—delivering faster study start-up, increased efficiency, and higher quality and compliance for everyone involved. 

About Inc. 

Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.inc.com.